Zhengyu Yang

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó et al. · The Lancet Diabetes & Endocrinology · 2022 · 252 citations · Full text

Metabolic Syndrome, Diabetes Management, Insulin Management +8

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew Wardley, Stefania Zambelli et al. · The Lancet Oncology · 2020 · 251 citations

Breast Oncology, Standard-of-care Chemotherapy, Medicine +7

Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice

Matthew R. Alexander, Christopher W. Moehle, Jason L. Johnson et al. · Journal of Clinical Investigation · 2011 · 212 citations · Full text

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun et al. · Clinical Cancer Research · 2020 · 189 citations